Celldex Therapeutics, Inc. (CLDX)
USD 14.93
(-5.42%)
USD 14.93
(-5.42%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -154.54 Million USD | -23.26% |
| 2022 | -115.23 Million USD | -61.75% |
| 2021 | -71.24 Million USD | -12.45% |
| 2020 | -63.35 Million USD | -15.12% |
| 2019 | -55.03 Million USD | 64.82% |
| 2018 | -156.43 Million USD | -28.73% |
| 2017 | -121.52 Million USD | 8.57% |
| 2016 | -132.91 Million USD | -2.61% |
| 2015 | -129.54 Million USD | -5.81% |
| 2014 | -122.43 Million USD | -50.33% |
| 2013 | -81.44 Million USD | -40.23% |
| 2012 | -58.07 Million USD | -33.82% |
| 2011 | -43.39 Million USD | -572.33% |
| 2010 | -6.45 Million USD | 82.48% |
| 2009 | -36.85 Million USD | 24.42% |
| 2008 | -48.75 Million USD | -113.33% |
| 2007 | -22.85 Million USD | -2.18% |
| 2006 | -22.36 Million USD | -18.56% |
| 2005 | -18.86 Million USD | -38.89% |
| 2004 | -13.58 Million USD | -15.75% |
| 2003 | -11.73 Million USD | 18.69% |
| 2002 | -14.43 Million USD | 41.24% |
| 2001 | -24.56 Million USD | -59.07% |
| 2000 | -15.44 Million USD | -29.27% |
| 1999 | -11.94 Million USD | -51.19% |
| 1998 | -7.9 Million USD | -2.6% |
| 1997 | -7.7 Million USD | 34.75% |
| 1996 | -11.8 Million USD | 0.0% |
| 1995 | -11.8 Million USD | -24.21% |
| 1994 | -9.5 Million USD | -1.06% |
| 1993 | -9.4 Million USD | -100.0% |
| 1992 | -4.7 Million USD | -6.82% |
| 1991 | -4.4 Million USD | -131.58% |
| 1990 | -1.9 Million USD | -18.75% |
| 1989 | -1.6 Million USD | 20.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -46.31 Million USD | -14.06% |
| 2024 Q1 | -40.6 Million USD | -15.6% |
| 2023 Q3 | -41.23 Million USD | -24.2% |
| 2023 Q1 | -32.47 Million USD | -16.45% |
| 2023 Q4 | -35.12 Million USD | 14.82% |
| 2023 Q2 | -33.2 Million USD | -2.26% |
| 2023 FY | -142.04 Million USD | -23.26% |
| 2022 FY | -115.23 Million USD | -61.75% |
| 2022 Q1 | -23.25 Million USD | -14.34% |
| 2022 Q2 | -36.39 Million USD | -56.49% |
| 2022 Q3 | -27.69 Million USD | 23.9% |
| 2022 Q4 | -27.88 Million USD | -0.68% |
| 2021 Q3 | -20.82 Million USD | -54.94% |
| 2021 Q4 | -20.34 Million USD | 2.32% |
| 2021 FY | -71.24 Million USD | -12.45% |
| 2021 Q2 | -13.44 Million USD | 19.23% |
| 2021 Q1 | -16.63 Million USD | 32.85% |
| 2020 FY | -63.35 Million USD | -15.12% |
| 2020 Q2 | -11.36 Million USD | 11.67% |
| 2020 Q3 | -14.34 Million USD | -26.19% |
| 2020 Q4 | -24.78 Million USD | -72.78% |
| 2020 Q1 | -12.86 Million USD | 0.94% |
| 2019 Q3 | -11.84 Million USD | 3.37% |
| 2019 FY | -55.03 Million USD | 64.82% |
| 2019 Q1 | -17.94 Million USD | -48.0% |
| 2019 Q2 | -12.25 Million USD | 31.68% |
| 2019 Q4 | -12.98 Million USD | -9.67% |
| 2018 Q3 | -7.76 Million USD | 53.99% |
| 2018 Q4 | -12.12 Million USD | -56.13% |
| 2018 Q1 | -119.67 Million USD | -368.84% |
| 2018 Q2 | -16.87 Million USD | 85.9% |
| 2018 FY | -156.43 Million USD | -28.73% |
| 2017 Q2 | -28.92 Million USD | 17.61% |
| 2017 Q4 | -25.52 Million USD | 20.13% |
| 2017 FY | -121.52 Million USD | 8.57% |
| 2017 Q1 | -35.11 Million USD | -0.75% |
| 2017 Q3 | -31.96 Million USD | -10.48% |
| 2016 Q2 | -32.36 Million USD | 9.35% |
| 2016 FY | -132.91 Million USD | -2.61% |
| 2016 Q4 | -34.85 Million USD | -16.2% |
| 2016 Q1 | -35.7 Million USD | -6.78% |
| 2016 Q3 | -29.99 Million USD | 7.33% |
| 2015 FY | -129.54 Million USD | -5.81% |
| 2015 Q1 | -30.98 Million USD | 3.34% |
| 2015 Q4 | -33.43 Million USD | -3.3% |
| 2015 Q2 | -32.75 Million USD | -5.71% |
| 2015 Q3 | -32.37 Million USD | 1.16% |
| 2014 Q2 | -28.54 Million USD | 9.34% |
| 2014 Q4 | -32.05 Million USD | -5.63% |
| 2014 FY | -122.43 Million USD | -50.33% |
| 2014 Q1 | -31.48 Million USD | -42.39% |
| 2014 Q3 | -30.34 Million USD | -6.28% |
| 2013 FY | -81.44 Million USD | -40.23% |
| 2013 Q1 | -17.4 Million USD | -5.14% |
| 2013 Q4 | -22.11 Million USD | 4.96% |
| 2013 Q3 | -23.26 Million USD | -24.71% |
| 2013 Q2 | -18.65 Million USD | -7.22% |
| 2012 Q1 | -13.28 Million USD | -7.31% |
| 2012 Q4 | -16.55 Million USD | -12.2% |
| 2012 FY | -58.07 Million USD | -33.82% |
| 2012 Q3 | -14.75 Million USD | -9.36% |
| 2012 Q2 | -13.48 Million USD | -1.51% |
| 2011 Q3 | -11.47 Million USD | -16.16% |
| 2011 FY | -43.39 Million USD | -572.33% |
| 2011 Q1 | -9.65 Million USD | -145.74% |
| 2011 Q4 | -12.38 Million USD | -7.88% |
| 2011 Q2 | -9.88 Million USD | -2.31% |
| 2010 Q3 | -8.87 Million USD | 4.38% |
| 2010 Q2 | -9.28 Million USD | 1.29% |
| 2010 Q4 | 21.11 Million USD | 337.82% |
| 2010 Q1 | -9.4 Million USD | 28.65% |
| 2010 FY | -6.45 Million USD | 82.48% |
| 2009 FY | -36.85 Million USD | 24.42% |
| 2009 Q1 | -7.78 Million USD | -1.9% |
| 2009 Q2 | -8.72 Million USD | -12.03% |
| 2009 Q3 | -7.15 Million USD | 17.96% |
| 2009 Q4 | -13.18 Million USD | -84.25% |
| 2008 Q3 | -8.57 Million USD | 17.2% |
| 2008 FY | -48.75 Million USD | -113.33% |
| 2008 Q1 | -22.17 Million USD | -309.87% |
| 2008 Q4 | -7.64 Million USD | 10.92% |
| 2008 Q2 | -10.35 Million USD | 53.29% |
| 2007 Q4 | -5.41 Million USD | 1.73% |
| 2007 Q1 | -6.06 Million USD | 13.53% |
| 2007 Q3 | -5.5 Million USD | 6.19% |
| 2007 FY | -22.85 Million USD | -2.18% |
| 2007 Q2 | -5.86 Million USD | 3.28% |
| 2006 Q4 | -7.01 Million USD | -14.22% |
| 2006 FY | -22.36 Million USD | -18.56% |
| 2006 Q1 | -2.87 Million USD | 32.68% |
| 2006 Q2 | -6.32 Million USD | -119.63% |
| 2006 Q3 | -6.14 Million USD | 2.84% |
| 2005 FY | -18.86 Million USD | -38.89% |
| 2005 Q4 | -4.27 Million USD | 8.29% |
| 2005 Q3 | -4.66 Million USD | 4.89% |
| 2005 Q2 | -4.9 Million USD | 2.31% |
| 2005 Q1 | -5.01 Million USD | -31.82% |
| 2004 FY | -13.58 Million USD | -15.75% |
| 2004 Q2 | -3.99 Million USD | -103.39% |
| 2004 Q4 | -3.8 Million USD | 0.25% |
| 2004 Q3 | -3.81 Million USD | 4.4% |
| 2004 Q1 | -1.96 Million USD | 31.98% |
| 2003 Q1 | -3.48 Million USD | 2.95% |
| 2003 Q2 | -3.19 Million USD | 8.29% |
| 2003 FY | -11.73 Million USD | 18.69% |
| 2003 Q3 | -2.16 Million USD | 32.17% |
| 2003 Q4 | -2.88 Million USD | -33.18% |
| 2002 Q2 | -5.32 Million USD | -4.1% |
| 2002 Q4 | -3.59 Million USD | -803.22% |
| 2002 Q1 | -5.11 Million USD | 28.22% |
| 2002 Q3 | -397.5 Thousand USD | 92.54% |
| 2002 FY | -14.43 Million USD | 41.24% |
| 2001 Q2 | -6.15 Million USD | -31.35% |
| 2001 Q3 | -6.58 Million USD | -6.93% |
| 2001 Q4 | -7.12 Million USD | -8.31% |
| 2001 FY | -24.56 Million USD | -59.07% |
| 2001 Q1 | -4.68 Million USD | 10.28% |
| 2000 FY | -15.44 Million USD | -29.27% |
| 2000 Q2 | -2.98 Million USD | -2.92% |
| 2000 Q1 | -2.9 Million USD | 26.4% |
| 2000 Q3 | -4.32 Million USD | -44.8% |
| 2000 Q4 | -5.22 Million USD | -20.72% |
| 1999 Q3 | -2.7 Million USD | -12.5% |
| 1999 FY | -11.94 Million USD | -51.19% |
| 1999 Q1 | -3 Million USD | -20.0% |
| 1999 Q4 | -3.94 Million USD | -46.09% |
| 1999 Q2 | -2.4 Million USD | 20.0% |
| 1998 Q1 | -1.5 Million USD | 11.76% |
| 1998 Q2 | -1.6 Million USD | -6.67% |
| 1998 Q3 | -2.3 Million USD | -43.75% |
| 1998 FY | -7.9 Million USD | -2.6% |
| 1998 Q4 | -2.5 Million USD | -8.7% |
| 1997 Q3 | -2.1 Million USD | -10.53% |
| 1997 Q1 | -2 Million USD | 25.93% |
| 1997 Q2 | -1.9 Million USD | 5.0% |
| 1997 Q4 | -1.7 Million USD | 19.05% |
| 1997 FY | -7.7 Million USD | 34.75% |
| 1996 Q1 | -2.2 Million USD | 31.25% |
| 1996 FY | -11.8 Million USD | 0.0% |
| 1996 Q4 | -2.7 Million USD | -17.39% |
| 1996 Q3 | -2.3 Million USD | 47.73% |
| 1996 Q2 | -4.4 Million USD | -100.0% |
| 1995 Q1 | -2.7 Million USD | -22.73% |
| 1995 Q2 | -2.6 Million USD | 3.7% |
| 1995 FY | -11.8 Million USD | -24.21% |
| 1995 Q4 | -3.2 Million USD | 3.03% |
| 1995 Q3 | -3.3 Million USD | -26.92% |
| 1994 Q3 | -2.5 Million USD | 3.85% |
| 1994 Q2 | -2.6 Million USD | -13.04% |
| 1994 Q1 | -2.3 Million USD | 8.0% |
| 1994 FY | -9.5 Million USD | -1.06% |
| 1994 Q4 | -2.2 Million USD | 12.0% |
| 1993 Q2 | -2 Million USD | 9.09% |
| 1993 Q4 | -2.5 Million USD | 13.79% |
| 1993 Q1 | -2.2 Million USD | 0.0% |
| 1993 Q3 | -2.9 Million USD | -45.0% |
| 1993 FY | -9.4 Million USD | -100.0% |
| 1992 Q1 | -1.9 Million USD | -137.5% |
| 1992 Q2 | -1.5 Million USD | 21.05% |
| 1992 FY | -4.7 Million USD | -6.82% |
| 1992 Q3 | -1.4 Million USD | 6.67% |
| 1991 Q3 | -2.1 Million USD | -23.53% |
| 1991 FY | -4.4 Million USD | -131.58% |
| 1991 Q2 | -1.7 Million USD | -30.77% |
| 1991 Q1 | -1.3 Million USD | -30.0% |
| 1991 Q4 | -800 Thousand USD | 61.9% |
| 1990 Q1 | 100 Thousand USD | 150.0% |
| 1990 FY | -1.9 Million USD | -18.75% |
| 1990 Q4 | -1 Million USD | 0.0% |
| 1990 Q3 | -1 Million USD | 16.67% |
| 1990 Q2 | -1.2 Million USD | -1300.0% |
| 1989 Q4 | -200 Thousand USD | -108.33% |
| 1989 Q1 | -7.1 Million USD | -473.68% |
| 1989 FY | -1.6 Million USD | 20.0% |
| 1989 Q3 | 2.4 Million USD | 14.29% |
| 1989 Q2 | 2.1 Million USD | 129.58% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AbCellera Biologics Inc. | -237.2 Million USD | 34.849% |
| Alkermes plc | 414.12 Million USD | 137.318% |
| Agenus Inc. | -159.54 Million USD | 3.138% |
| Aptorum Group Limited | -10.52 Million USD | -1368.566% |
| Ardelyx, Inc. | -63.27 Million USD | -144.235% |
| Dyadic International, Inc. | -8.22 Million USD | -1777.848% |
| Eton Pharmaceuticals, Inc. | -1.19 Million USD | -12864.933% |
| Lantern Pharma Inc. | -17.87 Million USD | -764.446% |
| Inhibikase Therapeutics, Inc. | -20.08 Million USD | -669.256% |
| Novavax, Inc. | -566.51 Million USD | 72.72% |
| Janux Therapeutics, Inc. | -72.97 Million USD | -111.762% |
| Pyxis Oncology, Inc. | -82.19 Million USD | -88.016% |
| TransCode Therapeutics, Inc. | -19.41 Million USD | -695.849% |
| Ocuphire Pharma, Inc. | -10.56 Million USD | -1363.05% |
| Outlook Therapeutics, Inc. | -53.12 Million USD | -190.895% |
| Madrigal Pharmaceuticals, Inc. | -380.49 Million USD | 59.384% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | -535.802% |
| SELLAS Life Sciences Group, Inc. | -37.86 Million USD | -308.096% |
| Syros Pharmaceuticals, Inc. | -128.98 Million USD | -19.811% |
| Barinthus Biotherapeutics plc | -83.91 Million USD | -84.167% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | -781.133% |
| Xeris Biopharma Holdings, Inc. | -44.01 Million USD | -251.152% |
| Clearside Biomedical, Inc. | -24.84 Million USD | -522.05% |
| C4 Therapeutics, Inc. | -139.03 Million USD | -11.157% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 45.232% |
| AlloVir, Inc. | -181.33 Million USD | 14.774% |
| Arrowhead Pharmaceuticals, Inc. | -205 Million USD | 24.614% |
| VYNE Therapeutics Inc. | -29.25 Million USD | -428.204% |
| Bicycle Therapeutics plc | -189.94 Million USD | 18.639% |
| BioXcel Therapeutics, Inc. | -171.78 Million USD | 10.036% |
| ChromaDex Corporation | -5.59 Million USD | -2660.171% |
| Chimerix, Inc. | -93.06 Million USD | -66.058% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | -242.838% |
| Caribou Biosciences, Inc. | -116.05 Million USD | -33.158% |
| CRISPR Therapeutics AG | -222.53 Million USD | 30.555% |
| Precision BioSciences, Inc. | -43.73 Million USD | -253.352% |
| Fate Therapeutics, Inc. | -190.51 Million USD | 18.88% |
| Fortress Biotech, Inc. | -142.34 Million USD | -8.571% |
| Fortress Biotech, Inc. | -142.34 Million USD | -8.571% |
| HOOKIPA Pharma Inc. | -97.69 Million USD | -58.19% |
| ImmuCell Corporation | -5.74 Million USD | -2588.586% |
| IDEAYA Biosciences, Inc. | -134.42 Million USD | -14.962% |
| Immix Biopharma, Inc. | -16.14 Million USD | -857.443% |
| Incyte Corporation | 620.52 Million USD | 124.905% |
| Innoviva, Inc. | 176.7 Million USD | 187.456% |
| IO Biotech, Inc. | -91.44 Million USD | -69.004% |
| Jaguar Health, Inc. | -34.29 Million USD | -350.678% |
| Keros Therapeutics, Inc. | -169.94 Million USD | 9.061% |
| Ligand Pharmaceuticals Incorporated | 11.94 Million USD | 1394.105% |
| ContextLogic Inc. | -328 Million USD | 52.884% |
| MiMedx Group, Inc. | 37.11 Million USD | 516.376% |
| MEI Pharma, Inc. | 14.54 Million USD | 1162.729% |
| NextCure, Inc. | -67.63 Million USD | -128.487% |
| Onconetix, Inc. | -36.03 Million USD | -328.871% |
| Oncternal Therapeutics, Inc. | -41.71 Million USD | -270.48% |
| Opthea Limited | -191.84 Million USD | 19.443% |
| Psyence Biomedical Ltd. | -2.75 Million USD | -5515.982% |
| Vaxcyte, Inc. | -468.04 Million USD | 66.981% |
| PDS Biotechnology Corporation | -43.04 Million USD | -259.022% |
| Precigen, Inc. | -88.92 Million USD | -73.793% |
| Pharming Group N.V. | -4.87 Million USD | -3067.14% |
| Phathom Pharmaceuticals, Inc. | -167.31 Million USD | 7.632% |
| Pieris Pharmaceuticals, Inc. | -29.75 Million USD | -419.364% |
| PureTech Health plc | -146.19 Million USD | -5.707% |
| Rigel Pharmaceuticals, Inc. | -20.49 Million USD | -654.195% |
| Avidity Biosciences, Inc. | -235.59 Million USD | 34.404% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | -535.802% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 43.599% |
| Sol-Gel Technologies Ltd. | -29.3 Million USD | -427.357% |
| Acelyrin, Inc. | -422.06 Million USD | 63.384% |
| Salarius Pharmaceuticals, Inc. | -12.89 Thousand USD | -1198370.098% |
| Summit Therapeutics Inc. | -89.73 Million USD | -72.219% |
| Sensei Biotherapeutics, Inc. | -37.06 Million USD | -316.96% |
| Senti Biosciences, Inc. | -92.72 Million USD | -66.663% |
| Stoke Therapeutics, Inc. | -114.77 Million USD | -34.65% |
| Elevation Oncology, Inc. | -45.44 Million USD | -240.064% |
| Alaunos Therapeutics, Inc. | -34.26 Million USD | -350.994% |
| Telomir Pharmaceuticals, Inc. Common Stock | -3.94 Million USD | -3820.348% |
| Entrada Therapeutics, Inc. | -3.16 Million USD | -4787.476% |
| VistaGen Therapeutics, Inc. | -33.02 Million USD | -368.011% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | -1717.927% |
| Wave Life Sciences Ltd. | -67.99 Million USD | -127.281% |
| Seer, Inc. | -103.46 Million USD | -49.369% |
| Verrica Pharmaceuticals Inc. | -65.75 Million USD | -135.013% |
| Aadi Bioscience, Inc. | -71.93 Million USD | -114.842% |
| ESSA Pharma Inc. | -32.13 Million USD | -380.928% |
| GlycoMimetics, Inc. | -39.27 Million USD | -293.484% |
| GT Biopharma, Inc. | -13.57 Million USD | -1038.347% |
| Inhibrx Biosciences, Inc. | -219.22 Million USD | 29.504% |
| Akebia Therapeutics, Inc. | -46.25 Million USD | -234.102% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | 278.019% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | -172.278% |
| Orchestra BioMed Holdings, Inc. | -51.5 Million USD | -200.047% |
| Alzamend Neuro, Inc. | -9.93 Million USD | -1455.117% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 69.356% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | -2140.389% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | -204.859% |
| Rocket Pharmaceuticals, Inc. | -259.65 Million USD | 40.483% |
| Aptose Biosciences Inc. | -52.35 Million USD | -195.175% |
| ZyVersa Therapeutics, Inc. | -14.42 Million USD | -971.662% |
| Soligenix, Inc. | -7.69 Million USD | -1907.576% |
| Century Therapeutics, Inc. | -146.54 Million USD | -5.456% |
| Kura Oncology, Inc. | -165.8 Million USD | 6.792% |
| TScan Therapeutics, Inc. | -93.45 Million USD | -65.36% |
| Intensity Therapeutics, Inc. | -8.31 Million USD | -1757.699% |
| Ocean Biomedical, Inc. | -2.48 Million USD | -6127.417% |
| CytomX Therapeutics, Inc. | -6.48 Million USD | -2283.436% |
| Autolus Therapeutics plc | -195.02 Million USD | 20.759% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | -82.551% |
| EyePoint Pharmaceuticals, Inc. | -73.66 Million USD | -109.799% |
| Eterna Therapeutics Inc. | -21.13 Million USD | -631.214% |
| Adaptive Biotechnologies Corporation | -227.03 Million USD | 31.93% |
| GRI Bio, Inc. | -11.38 Million USD | -1257.179% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | -3322.315% |
| Tenaya Therapeutics, Inc. | -131.19 Million USD | -17.797% |
| IGM Biosciences, Inc. | -263.46 Million USD | 41.342% |
| INmune Bio, Inc. | -29.74 Million USD | -419.626% |
| Heron Therapeutics, Inc. | -110.61 Million USD | -39.712% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | -305.885% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | -867.135% |
| Entero Therapeutics, Inc. | -15.77 Million USD | -879.923% |
| Milestone Pharmaceuticals Inc. | -61.09 Million USD | -152.941% |
| X4 Pharmaceuticals, Inc. | -107.52 Million USD | -43.731% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 44.008% |
| Coherus BioSciences, Inc. | -203.19 Million USD | 23.945% |
| Verastem, Inc. | -92.08 Million USD | -67.827% |
| Abeona Therapeutics Inc. | -47.13 Million USD | -227.871% |
| Pliant Therapeutics, Inc. | -184.14 Million USD | 16.076% |
| Tonix Pharmaceuticals Holding Corp. | -118.38 Million USD | -30.547% |
| Histogen Inc. | -10.64 Million USD | -1352.053% |
| Aprea Therapeutics, Inc. | -15.47 Million USD | -898.852% |
| Surrozen, Inc. | -45.78 Million USD | -237.575% |
| Organovo Holdings, Inc. | -15.08 Million USD | -924.407% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | -2936.048% |
| Ovid Therapeutics Inc. | -59.28 Million USD | -160.692% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | -201.287% |
| CASI Pharmaceuticals, Inc. | -25.28 Million USD | -511.321% |
| Cadrenal Therapeutics, Inc. Common Stock | -7.63 Million USD | -1924.698% |
| Centessa Pharmaceuticals plc | -171.28 Million USD | 9.774% |
| Hepion Pharmaceuticals, Inc. | -48.44 Million USD | -218.986% |
| Arcturus Therapeutics Holdings Inc. | -78.2 Million USD | -97.611% |
| BioRestorative Therapies, Inc. | -15.22 Million USD | -915.336% |
| Apollomics, Inc. | -54.83 Million USD | -181.836% |
| Amarin Corporation plc | -67.58 Million USD | -128.653% |
| Mesoblast Limited | -58.79 Million USD | -162.853% |
| Turnstone Biologics Corp. | -59.03 Million USD | -161.794% |
| Kymera Therapeutics, Inc. | -165.53 Million USD | 6.638% |
| Synaptogenix, Inc. | -8.31 Million USD | -1758.849% |
| Tiziana Life Sciences Ltd | -14.58 Million USD | -959.523% |
| Aurinia Pharmaceuticals Inc. | -91.69 Million USD | -68.547% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -3125.359% |
| Monopar Therapeutics Inc. | -8.83 Million USD | -1649.948% |
| Exelixis, Inc. | 170.88 Million USD | 190.436% |
| Better Therapeutics, Inc. | -38.26 Million USD | -303.905% |
| Nurix Therapeutics, Inc. | -155.06 Million USD | 0.336% |
| Apellis Pharmaceuticals, Inc. | -517.12 Million USD | 70.115% |
| NLS Pharmaceutics AG | -11.8 Million USD | -1208.895% |
| Dermata Therapeutics, Inc. | -8.04 Million USD | -1821.709% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | -415.26% |
| Gritstone bio, Inc. | -154.63 Million USD | 0.059% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | -124.426% |
| TNF Pharmaceuticals, Inc. | -17.12 Million USD | -802.538% |
| Avid Bioservices, Inc. | -18.67 Million USD | -727.401% |
| Insmed Incorporated | -709.62 Million USD | 78.222% |
| Virpax Pharmaceuticals, Inc. | -15.68 Million USD | -884.985% |
| MediWound Ltd. | -15.29 Million USD | -910.739% |
| OmniAb, Inc. | -69.41 Million USD | -122.622% |
| Alector, Inc. | -151.74 Million USD | -1.847% |
| Seres Therapeutics, Inc. | -107.98 Million USD | -43.117% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | -196.353% |
| Zai Lab Limited | -366.57 Million USD | 57.841% |
| Revance Therapeutics, Inc. | -316.77 Million USD | 51.214% |
| Aura Biosciences, Inc. | -84.99 Million USD | -81.833% |
| Lyell Immunopharma, Inc. | -245.49 Million USD | 37.05% |
| Immunic, Inc. | -99.22 Million USD | -55.752% |
| Tarsus Pharmaceuticals, Inc. | -143.15 Million USD | -7.952% |
| Veracyte, Inc. | -85.79 Million USD | -80.129% |
| InMed Pharmaceuticals Inc. | - USD | Infinity% |
| FibroGen, Inc. | -281.81 Million USD | 45.162% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | -987.558% |
| Adial Pharmaceuticals, Inc. | -6.88 Million USD | -2143.658% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.79 Million USD | -722.355% |
| Jazz Pharmaceuticals plc | 578.58 Million USD | 126.711% |
| Cyclacel Pharmaceuticals, Inc. | -25.45 Million USD | -507.166% |
| Amylyx Pharmaceuticals, Inc. | 38.8 Million USD | 498.284% |
| TG Therapeutics, Inc. | 20.63 Million USD | 849.004% |
| Galecto, Inc. | -39.9 Million USD | -287.275% |
| Calithera Biosciences, Inc. | -42.07 Million USD | -267.31% |
| Fortrea Holdings Inc. | 63.1 Million USD | 344.916% |
| KalVista Pharmaceuticals, Inc. | -140.44 Million USD | -10.037% |
| Aptevo Therapeutics Inc. | -28.87 Million USD | -435.155% |
| XBiotech Inc. | -37.51 Million USD | -312.002% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | -124.426% |
| Lyra Therapeutics, Inc. | -67.12 Million USD | -130.247% |
| Foghorn Therapeutics Inc. | -107.9 Million USD | -43.219% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | -501.987% |
| Theravance Biopharma, Inc. | -53.29 Million USD | -189.991% |
| Ultragenyx Pharmaceutical Inc. | -569.2 Million USD | 72.85% |
| Metagenomi, Inc. Common Stock | -78.49 Million USD | -96.889% |
| Vaxxinity, Inc. | -58.28 Million USD | -165.149% |
| BioCryst Pharmaceuticals, Inc. | -103.7 Million USD | -49.015% |
| Gain Therapeutics, Inc. | -22.25 Million USD | -594.473% |
| Cartesian Therapeutics, Inc. | -86.41 Million USD | -78.835% |
| NexImmune, Inc. | -29.19 Million USD | -429.39% |
| Creative Medical Technology Holdings, Inc. | -5.62 Million USD | -2649.793% |
| Marker Therapeutics, Inc. | -14.58 Million USD | -959.859% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 103.819% |
| Chemomab Therapeutics Ltd. | -25.45 Million USD | -507.023% |
| Scopus BioPharma Inc. | -11.71 Million USD | -1219.194% |
| RAPT Therapeutics, Inc. | -127.06 Million USD | -21.627% |
| Ainos, Inc. | -13.2 Million USD | -1070.206% |
| Pluri Inc. | -22.15 Million USD | -597.455% |
| Prothena Corporation plc | -191.03 Million USD | 19.103% |
| Adaptimmune Therapeutics plc | -138.03 Million USD | -11.956% |
| Celularity Inc. | -192.28 Million USD | 19.63% |
| Rallybio Corporation | -78.93 Million USD | -95.791% |
| Cue Biopharma, Inc. | -52.14 Million USD | -196.347% |
| MeiraGTx Holdings plc | -137.06 Million USD | -12.754% |
| Omeros Corporation | -164.53 Million USD | 6.071% |
| Humacyte, Inc. | -100.04 Million USD | -54.469% |
| Immunocore Holdings plc | -59.64 Million USD | -159.086% |
| Cocrystal Pharma, Inc. | -18.55 Million USD | -732.707% |
| Cidara Therapeutics, Inc. | -24.48 Million USD | -531.222% |
| Blueprint Medicines Corporation | -486.27 Million USD | 68.219% |
| CalciMedica, Inc. | -21.87 Million USD | -606.478% |
| Cabaletta Bio, Inc. | -74.66 Million USD | -106.994% |
| Marinus Pharmaceuticals, Inc. | -131.48 Million USD | -17.536% |
| Scholar Rock Holding Corporation | -171.29 Million USD | 9.78% |
| Sana Biotechnology, Inc. | -326.9 Million USD | 52.725% |
| Pulmatrix, Inc. | -14.74 Million USD | -948.453% |
| Elicio Therapeutics, Inc. | -35.74 Million USD | -332.346% |
| Vigil Neuroscience, Inc. | -88.86 Million USD | -73.905% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 70.009% |
| Adlai Nortye Ltd. American Depositary Shares | -67.55 Million USD | -128.778% |
| Cytokinetics, Incorporated | -496.2 Million USD | 68.855% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | -349.002% |
| Nutriband Inc. | -4.87 Million USD | -3072.093% |
| Protara Therapeutics, Inc. | -43.61 Million USD | -254.348% |
| Vor Biopharma Inc. | -126.03 Million USD | -22.617% |
| Roivant Sciences Ltd. | 4.24 Billion USD | 103.643% |
| Evogene Ltd. | -26.39 Million USD | -485.586% |
| ProKidney Corp. | -151.52 Million USD | -1.993% |
| Applied Therapeutics, Inc. | -64.53 Million USD | -139.47% |
| Hoth Therapeutics, Inc. | -7.69 Million USD | -1909.063% |
| BridgeBio Pharma, Inc. | -607.37 Million USD | 74.556% |
| CorMedix Inc. | -48.95 Million USD | -215.664% |
| BioLineRx Ltd. | -49.69 Million USD | -210.987% |
| Tango Therapeutics, Inc. | -114.17 Million USD | -35.358% |
| Galectin Therapeutics Inc. | -38.07 Million USD | -305.92% |
| Atai Life Sciences N.V. | -125.47 Million USD | -23.169% |
| Renovaro Biosciences Inc. | -81.63 Million USD | -89.299% |
| Aerovate Therapeutics, Inc. | -81.4 Million USD | -89.834% |
| Zentalis Pharmaceuticals, Inc. | -248.98 Million USD | 37.932% |
| Sagimet Biosciences Inc. | -30.74 Million USD | -402.739% |
| MediciNova, Inc. | -9.9 Million USD | -1460.989% |
| Praxis Precision Medicines, Inc. | -126.37 Million USD | -22.29% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | -2033.833% |
| GeoVax Labs, Inc. | -26.74 Million USD | -477.88% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 33.337% |
| Biomea Fusion, Inc. | -126.13 Million USD | -22.521% |
| PTC Therapeutics, Inc. | -349.4 Million USD | 55.77% |
| Mereo BioPharma Group plc | -28.41 Million USD | -443.856% |
| Cullinan Oncology, Inc. | -191.08 Million USD | 19.126% |
| Syndax Pharmaceuticals, Inc. | -229.95 Million USD | 32.794% |
| Absci Corporation | -115.51 Million USD | -33.785% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | -460.199% |
| 4D Molecular Therapeutics, Inc. | -112.86 Million USD | -36.924% |
| Dyne Therapeutics, Inc. | -242.16 Million USD | 36.182% |
| Kiniksa Pharmaceuticals, Ltd. | -25.19 Million USD | -513.359% |
| Ventyx Biosciences, Inc. | -207.99 Million USD | 25.699% |
| Allakos Inc. | -196.05 Million USD | 21.175% |
| Imunon, Inc. | -21.03 Million USD | -634.849% |
| Fulcrum Therapeutics, Inc. | -110.66 Million USD | -39.65% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 244.052% |
| BioAtla, Inc. | -129.68 Million USD | -19.165% |
| NLS Pharmaceutics AG | -11.8 Million USD | -1208.895% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | -875.459% |
| Allogene Therapeutics, Inc. | -327.73 Million USD | 52.846% |
| Larimar Therapeutics, Inc. | -41.75 Million USD | -270.09% |
| XOMA Corporation | -41.84 Million USD | -269.294% |
| Kezar Life Sciences, Inc. | -105.23 Million USD | -46.851% |
| Cara Therapeutics, Inc. | -121.49 Million USD | -27.2% |
| aTyr Pharma, Inc. | -54.91 Million USD | -181.4% |
| Aligos Therapeutics, Inc. | -87.42 Million USD | -76.767% |
| Akero Therapeutics, Inc. | -172.87 Million USD | 10.602% |
| Viridian Therapeutics, Inc. | -254.45 Million USD | 39.264% |
| Eliem Therapeutics, Inc. | -21.46 Million USD | -619.939% |
| EyeGate Pharmaceuticals, Inc. | -8.21 Million USD | -1781.732% |
| Akari Therapeutics, Plc | -16.8 Million USD | -819.564% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | -1747513.657% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 145.78% |
| Lexaria Bioscience Corp. | -6.53 Million USD | -2265.189% |
| UroGen Pharma Ltd. | -65.53 Million USD | -135.812% |
| Sutro Biopharma, Inc. | -89.27 Million USD | -73.102% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -2027.795% |
| Orgenesis Inc. | -53.63 Million USD | -188.131% |
| Entera Bio Ltd. | -8.89 Million USD | -1638.185% |
| GH Research PLC | -41.22 Million USD | -274.902% |
| Lisata Therapeutics, Inc. | -25.7 Million USD | -501.144% |
| Reneo Pharmaceuticals, Inc. | -83.05 Million USD | -86.076% |
| Xencor, Inc. | -138.63 Million USD | -11.471% |
| 60 Degrees Pharmaceuticals, Inc. | -5.15 Million USD | -2898.147% |
| Replimune Group, Inc. | -234.77 Million USD | 34.174% |
| Coeptis Therapeutics Holdings, Inc. | -21.49 Million USD | -619.097% |
| Vanda Pharmaceuticals Inc. | -13.95 Million USD | -1007.669% |
| Lexaria Bioscience Corp. | -6.53 Million USD | -2265.189% |
| Portage Biotech Inc. | -18.25 Million USD | -746.666% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | -2033.833% |
| Olema Pharmaceuticals, Inc. | -104.96 Million USD | -47.238% |
| OncoCyte Corporation | -25.13 Million USD | -514.823% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | -1267.041% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | -1248.88% |
| Purple Biotech Ltd. | 22.27 Million USD | 793.916% |
| CollPlant Biotechnologies Ltd. | -7.51 Million USD | -1957.268% |
| scPharmaceuticals Inc. | -55.39 Million USD | -178.977% |
| ProMIS Neurosciences, Inc. | -18.89 Million USD | -717.782% |
| HilleVax, Inc. | -133.34 Million USD | -15.896% |
| NeuroSense Therapeutics Ltd. | -12.04 Million USD | -1182.613% |
| Tharimmune, Inc. | -9.45 Million USD | -1534.462% |
| Genprex, Inc. | -31.07 Million USD | -397.31% |
| Neumora Therapeutics, Inc. Common Stock | -188.19 Million USD | 17.882% |
| Atossa Therapeutics, Inc. | -31.37 Million USD | -392.533% |
| XTL Biopharmaceuticals Ltd. | -765 Thousand USD | -20101.569% |
| Virios Therapeutics, Inc. | -5.44 Million USD | -2737.237% |
| OKYO Pharma Limited | -15.74 Thousand USD | -981135.869% |
| Savara Inc. | -60 Million USD | -157.54% |
| Curis, Inc. | -48.33 Million USD | -219.751% |
| Daré Bioscience, Inc. | -30.83 Million USD | -401.111% |
| Carmell Therapeutics Corporation | -5.21 Million USD | -2862.118% |
| Titan Pharmaceuticals, Inc. | -7.27 Million USD | -2023.705% |
| Achieve Life Sciences, Inc. | -27.25 Million USD | -467.127% |
| BeiGene, Ltd. | -1.2 Billion USD | 87.204% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | -675.062% |
| Revolution Medicines, Inc. Warrant | -487.18 Million USD | 68.279% |
| Protagonist Therapeutics, Inc. | -93.65 Million USD | -65.017% |
| Erasca, Inc. | -141.52 Million USD | -9.198% |
| bluebird bio, Inc. | -244.26 Million USD | 36.731% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | -3313.804% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 179.48% |
| DBV Technologies S.A. | -76.43 Million USD | -102.195% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | -3313.804% |
| Moderna, Inc. | -4.23 Billion USD | 96.354% |
| Vincerx Pharma, Inc. | -42.6 Million USD | -262.698% |
| Fresh Tracks Therapeutics, Inc. | -6.36 Million USD | -2329.906% |
| Molecular Templates, Inc. | -10.46 Million USD | -1376.61% |
| Acrivon Therapeutics, Inc. Common Stock | -67.23 Million USD | -129.847% |
| Travere Therapeutics, Inc. | -376.74 Million USD | 58.98% |
| Monte Rosa Therapeutics, Inc. | -143.31 Million USD | -7.837% |
| Spruce Biosciences, Inc. | -51.99 Million USD | -197.236% |
| Cogent Biosciences, Inc. | -208.13 Million USD | 25.747% |
| MacroGenics, Inc. | -168.24 Million USD | 8.144% |
| RenovoRx, Inc. | -11.39 Million USD | -1256.107% |
| Adicet Bio, Inc. | -152.03 Million USD | -1.647% |
| Prime Medicine, Inc. | -191.29 Million USD | 19.211% |
| Aditxt, Inc. | -26.06 Million USD | -492.969% |
| Adagene Inc. | -23.71 Million USD | -551.53% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -2014.089% |
| Quantum-Si incorporated | -111.17 Million USD | -39.013% |
| Maravai LifeSciences Holdings, Inc. | -31.64 Million USD | -388.315% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | -960.121% |
| Voyager Therapeutics, Inc. | 122.01 Million USD | 226.659% |
| SciSparc Ltd. | -5.77 Million USD | -2576.979% |
| Vericel Corporation | -6.46 Million USD | -2290.811% |
| Revelation Biosciences, Inc. | -8.65 Million USD | -1685.237% |
| Minerva Neurosciences, Inc. | -23.11 Million USD | -568.447% |
| Generation Bio Co. | -138.56 Million USD | -11.532% |
| Astria Therapeutics, Inc. | -83.03 Million USD | -86.128% |
| Black Diamond Therapeutics, Inc. | -86.46 Million USD | -78.744% |
| Arcutis Biotherapeutics, Inc. | -241.1 Million USD | 35.902% |
| Invivyd, Inc. | -207.78 Million USD | 25.623% |
| Relay Therapeutics, Inc. | -373 Million USD | 58.568% |
| Quoin Pharmaceuticals, Ltd. | -9.37 Million USD | -1547.832% |
| Spero Therapeutics, Inc. | 21.48 Million USD | 819.436% |
| Artelo Biosciences, Inc. | -10.28 Million USD | -1402.304% |
| 2seventy bio, Inc. | -216.7 Million USD | 28.685% |
| ADMA Biologics, Inc. | 21.63 Million USD | 814.414% |
| Clene Inc. | -40.54 Million USD | -281.209% |
| Capricor Therapeutics, Inc. | -24.07 Million USD | -541.843% |
| Boundless Bio, Inc. Common Stock | -54.79 Million USD | -182.032% |
| GeoVax Labs, Inc. | -26.74 Million USD | -477.88% |
| Recursion Pharmaceuticals, Inc. | -350.06 Million USD | 55.853% |
| Citius Pharmaceuticals, Inc. | -36.73 Million USD | -320.728% |
| Contineum Therapeutics, Inc. Class A Common Stock | 16.07 Million USD | 1061.261% |
| Relmada Therapeutics, Inc. | -103.7 Million USD | -49.025% |
| Finch Therapeutics Group, Inc. | -34 Million USD | -354.509% |
| ALX Oncology Holdings Inc. | -170.27 Million USD | 9.241% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 77.416% |
| Evaxion Biotech A/S | -22.19 Million USD | -596.229% |
| Ocular Therapeutix, Inc. | -82.38 Million USD | -87.592% |
| Verve Therapeutics, Inc. | -223.12 Million USD | 30.737% |
| Trevena, Inc. | -35.28 Million USD | -337.945% |
| Surrozen, Inc. | -45.78 Million USD | -237.575% |
| Tyra Biosciences, Inc. | -79.94 Million USD | -93.31% |
| Cingulate Inc. | -22.75 Million USD | -579.031% |
| Galmed Pharmaceuticals Ltd. | 7.49 Million USD | 2162.76% |
| Unity Biotechnology, Inc. | -44.66 Million USD | -245.987% |
| Tenax Therapeutics, Inc. | -8.23 Million USD | -1776.89% |
| Terns Pharmaceuticals, Inc. | -102.55 Million USD | -50.687% |
| ACADIA Pharmaceuticals Inc. | -73.37 Million USD | -110.608% |
| Connect Biopharma Holdings Limited | -62.07 Million USD | -148.964% |
| Clearmind Medicine Inc. | -8.74 Million USD | -1667.942% |
| Kronos Bio, Inc. | -121.83 Million USD | -26.851% |
| Bolt Biotherapeutics, Inc. | -76.19 Million USD | -102.822% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | -5169.103% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -53.274% |
| Statera Biopharma, Inc. | -98.34 Million USD | -57.145% |
| ImmunityBio, Inc. | -362.25 Million USD | 57.338% |
| Korro Bio, Inc. | -84.53 Million USD | -82.816% |
| Kineta, Inc. | -15.72 Million USD | -882.904% |
| BioVie Inc. | -32.17 Million USD | -380.249% |
| Codexis, Inc. | -68.06 Million USD | -127.037% |
| Celularity Inc. | -192.28 Million USD | 19.63% |
| Crinetics Pharmaceuticals, Inc. | -222.6 Million USD | 30.577% |
| Celcuity Inc. | -66.23 Million USD | -133.34% |
| Virax Biolabs Group Limited | -6.49 Million USD | -2278.86% |
| Cibus, Inc. | -318.88 Million USD | 51.536% |
| Eledon Pharmaceuticals, Inc. | -43 Million USD | -259.4% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | -356.63% |
| IN8bio, Inc. | -30.33 Million USD | -409.418% |
| Kodiak Sciences Inc. | -277.32 Million USD | 44.273% |
| Annexon, Inc. | -143.72 Million USD | -7.528% |
| Adverum Biotechnologies, Inc. | -123.79 Million USD | -24.841% |
| Assembly Biosciences, Inc. | -64.64 Million USD | -139.059% |
| Avalo Therapeutics, Inc. | -23.44 Million USD | -559.196% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 56.311% |
| Eyenovia, Inc. | -25.4 Million USD | -508.279% |
| Puma Biotechnology, Inc. | 32.64 Million USD | 573.474% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | -2678.533% |
| Xilio Therapeutics, Inc. | -79.13 Million USD | -95.294% |
| Arcellx, Inc. | -89.88 Million USD | -71.943% |
| Cardiff Oncology, Inc. | -45.41 Million USD | -240.311% |
| Enanta Pharmaceuticals, Inc. | -137.2 Million USD | -12.634% |
| Regulus Therapeutics Inc. | -31.1 Million USD | -396.776% |
| Moolec Science SA | -6.65 Million USD | -2222.611% |
| Acumen Pharmaceuticals, Inc. | -61.13 Million USD | -152.776% |
| Geron Corporation | -193.94 Million USD | 20.316% |
| LAVA Therapeutics N.V. | -43.25 Million USD | -257.298% |
| Royalty Pharma plc | 1.49 Billion USD | 110.357% |
| Atea Pharmaceuticals, Inc. | -164.16 Million USD | 5.86% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | -1556.778% |
| TFF Pharmaceuticals, Inc. | -21.89 Million USD | -605.843% |
| Mersana Therapeutics, Inc. | -170.95 Million USD | 9.602% |
| Humacyte, Inc. | -100.04 Million USD | -54.469% |
| Structure Therapeutics Inc. | -102.77 Million USD | -50.369% |
| 89bio, Inc. | -151.2 Million USD | -2.208% |
| PMV Pharmaceuticals, Inc. | -80.13 Million USD | -92.859% |
| Avenue Therapeutics, Inc. | -14.54 Million USD | -962.875% |
| Genelux Corporation | -24.16 Million USD | -539.528% |
| Trevi Therapeutics, Inc. | -33.92 Million USD | -355.567% |
| Lexicon Pharmaceuticals, Inc. | -171.75 Million USD | 10.019% |
| Notable Labs, Ltd. | -14.65 Million USD | -954.39% |
| Liquidia Corporation | -73.38 Million USD | -110.594% |
| Mustang Bio, Inc. | -50.72 Million USD | -204.66% |
| Immunovant, Inc. | -282.7 Million USD | 45.335% |
| Quantum-Si incorporated | -111.17 Million USD | -39.013% |
| Arbutus Biopharma Corporation | -78.1 Million USD | -97.869% |
| DiaMedica Therapeutics Inc. | -21.26 Million USD | -626.675% |
| Vera Therapeutics, Inc. | -102.01 Million USD | -51.494% |
| Acasti Pharma Inc. | -11.31 Million USD | -1266.178% |
| MiNK Therapeutics, Inc. | -22.92 Million USD | -574.235% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | -867.135% |
| Xenon Pharmaceuticals Inc. | -214.05 Million USD | 27.802% |
| Elevai Labs, Inc. Common Stock | -3.66 Million USD | -4112.019% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | -872.819% |
| Tempest Therapeutics, Inc. | -29.15 Million USD | -430.034% |
| Soleno Therapeutics, Inc. | -41.38 Million USD | -273.434% |
| PepGen Inc. | -84.76 Million USD | -82.316% |
| Moleculin Biotech, Inc. | -29.63 Million USD | -421.555% |
| United Therapeutics Corporation | 1.18 Billion USD | 113.043% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | -574.944% |
| Solid Biosciences Inc. | -104.31 Million USD | -48.149% |
| BriaCell Therapeutics Corp. | -32.8 Million USD | -371.048% |
| Immuneering Corporation | -58.41 Million USD | -164.568% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | -2936.048% |
| Silo Pharma, Inc. | -3.85 Million USD | -3908.256% |
| Belite Bio, Inc | -31.66 Million USD | -388.007% |
| XOMA Corporation | -41.84 Million USD | -269.294% |
| ARS Pharmaceuticals, Inc. | -67.52 Million USD | -128.883% |
| Bionomics Limited | -17.89 Billion USD | 99.136% |
| Apogee Therapeutics, Inc. | -93 Million USD | -66.169% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | 533.133% |
| uniQure N.V. | -282.87 Million USD | 45.367% |
| Cassava Sciences, Inc. | -105.95 Million USD | -45.854% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -2014.089% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | -19.334% |
| Forte Biosciences, Inc. | -32.48 Million USD | -375.719% |
| Anebulo Pharmaceuticals, Inc. | -8.3 Million USD | -1759.99% |
| Enlivex Therapeutics Ltd. | -29.39 Million USD | -425.742% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | -2678.533% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | -987.558% |
| FibroBiologics, Inc. Common Stock | -8.88 Million USD | -1638.576% |
| Altimmune, Inc. | -95.92 Million USD | -61.1% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | -110.278% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | 533.133% |
| Compugen Ltd. | -12.99 Million USD | -1089.517% |
| Peak Bio, Inc. | -1356.23 USD | -11394869.88% |
| Zevra Therapeutics, Inc. | -49.6 Million USD | -211.551% |
| Benitec Biopharma Inc. | -22.49 Million USD | -587.159% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 36.22% |
| NKGen Biotech, Inc. Common Stock | -29.74 Million USD | -419.539% |
| Zura Bio Limited | -62.63 Million USD | -146.722% |
| PolyPid Ltd. | -22.86 Million USD | -575.83% |
| Aileron Therapeutics, Inc. | -16.27 Million USD | -849.508% |
| NKGen Biotech, Inc. Warrants | -29.74 Million USD | -419.539% |
| Instil Bio, Inc. | -159.16 Million USD | 2.907% |
| argenx SE | -425.04 Million USD | 63.641% |
| Immunome, Inc. | -109.53 Million USD | -41.096% |
| Compass Therapeutics, Inc. | -50.36 Million USD | -206.856% |
| Verona Pharma plc | -67.83 Million USD | -127.834% |
| enGene Holdings Inc. Warrants | -26.06 Million USD | -493.024% |
| Shattuck Labs, Inc. | -91.95 Million USD | -68.059% |
| CervoMed Inc. | -7.81 Million USD | -1878.038% |
| LENZ Therapeutics, Inc. | -73.11 Million USD | -111.383% |
| Plus Therapeutics, Inc. | -13.32 Million USD | -1060.138% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | -220.8% |
| Moolec Science SA | -6.65 Million USD | -2222.611% |
| Enveric Biosciences, Inc. | -16.44 Million USD | -839.554% |
| Inovio Pharmaceuticals, Inc. | -135.22 Million USD | -14.284% |
| AnaptysBio, Inc. | -164.41 Million USD | 6.003% |
| Design Therapeutics, Inc. | -78.19 Million USD | -97.649% |
| Leap Therapeutics, Inc. | -87.04 Million USD | -77.551% |
| NeurAxis, Inc. | -6.66 Million USD | -2218.885% |
| Seelos Therapeutics, Inc. | -40.49 Million USD | -281.595% |
| Lumos Pharma, Inc. | -36.61 Million USD | -322.084% |
| Achilles Therapeutics plc | -75.25 Million USD | -105.358% |
| enGene Holdings Inc. Common Stock | -26.06 Million USD | -493.024% |
| 180 Life Sciences Corp. | -13.47 Million USD | -1046.667% |
| Opiant Pharmaceuticals, Inc. | 5.15 Million USD | 3097.143% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | -5169.103% |
| Nutriband Inc. | -4.87 Million USD | -3072.093% |
| ORIC Pharmaceuticals, Inc. | -110.78 Million USD | -39.504% |
| CG Oncology, Inc. Common stock | -55.44 Million USD | -178.71% |
| Fractyl Health, Inc. Common Stock | -50.83 Million USD | -204.001% |
| Rani Therapeutics Holdings, Inc. | -66.09 Million USD | -133.804% |
| MoonLake Immunotherapeutics | -54.12 Million USD | -185.538% |
| Palisade Bio, Inc. | -13.07 Million USD | -1082.418% |
| Tourmaline Bio, Inc. | -45.4 Million USD | -240.333% |
| Beam Therapeutics Inc. | -176.48 Million USD | 12.433% |
| Neurogene Inc. | -55.58 Million USD | -178.038% |
| Mirum Pharmaceuticals, Inc. | -109.15 Million USD | -41.582% |
| AEON Biopharma, Inc. | -48.42 Million USD | -219.11% |
| CARGO Therapeutics, Inc. Common Stock | -96.71 Million USD | -59.799% |
| Sesen Bio, Inc. | -25.9 Million USD | -496.48% |
| Enliven Therapeutics, Inc. | -83.52 Million USD | -85.016% |
| Kiora Pharmaceuticals, Inc. | -12.58 Million USD | -1127.801% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 66.445% |
| Taysha Gene Therapies, Inc. | -72.43 Million USD | -113.341% |
| Athira Pharma, Inc. | -125.46 Million USD | -23.174% |
| Vaccinex, Inc. | -22.88 Million USD | -575.298% |
| HCW Biologics Inc. | -25.71 Million USD | -500.929% |
| XOMA Corporation | -41.84 Million USD | -269.294% |
| Nektar Therapeutics | -137.42 Million USD | -12.456% |
| Arvinas, Inc. | -401.5 Million USD | 61.509% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | -1747513.657% |
| Merus N.V. | -156.54 Million USD | 1.281% |
| Omega Therapeutics, Inc. | -100.26 Million USD | -54.14% |
| Quince Therapeutics, Inc. | -34.62 Million USD | -346.395% |
| Rezolute, Inc. | -70.42 Million USD | -119.448% |
| Clene Inc. | -40.54 Million USD | -281.209% |
| Indaptus Therapeutics, Inc. | -16.37 Million USD | -843.568% |
| BeyondSpring Inc. | -23.11 Million USD | -568.608% |
| Synlogic, Inc. | -55.16 Million USD | -180.165% |
| Allarity Therapeutics, Inc. | -17.92 Million USD | -761.967% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | -1327.772% |
| Peak Bio, Inc. | -1356.23 USD | -11394869.88% |
| Werewolf Therapeutics, Inc. | -40.5 Million USD | -281.557% |
| Krystal Biotech, Inc. | -109.72 Million USD | -40.842% |
| Karyopharm Therapeutics Inc. | -129.53 Million USD | -19.301% |
| SpringWorks Therapeutics, Inc. | -343.01 Million USD | 54.946% |
| Lipella Pharmaceuticals Inc. | -4.74 Million USD | -3156.29% |
| MannKind Corporation | 8.67 Million USD | 1880.848% |
| Ikena Oncology, Inc. | -75.41 Million USD | -104.917% |
| Cyclerion Therapeutics, Inc. | -9.64 Million USD | -1501.97% |
| Gyre Therapeutics, Inc. | -67.23 Million USD | -129.871% |
| Gossamer Bio, Inc. | -183.75 Million USD | 15.9% |
| CohBar, Inc. | -12.38 Million USD | -1147.484% |
| Cognition Therapeutics, Inc. | -50.72 Million USD | -204.672% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | -460.199% |
| Legend Biotech Corporation | -439.48 Million USD | 64.836% |
| Mural Oncology plc | -194.63 Million USD | 20.6% |
| Biora Therapeutics, Inc. | -67.14 Million USD | -130.168% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | -857.197% |
| Disc Medicine, Inc. | -91.12 Million USD | -69.593% |
| Champions Oncology, Inc. | -7.35 Million USD | -2000.897% |
| REGENXBIO Inc. | -268.12 Million USD | 42.363% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | -1341.867% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -177.176% |
| Cellectar Biosciences, Inc. | -38.96 Million USD | -296.662% |
| Edgewise Therapeutics, Inc. | -114.35 Million USD | -35.14% |
| Vaxart, Inc. | -83.34 Million USD | -85.42% |
| PharmaCyte Biotech, Inc. | -8.52 Million USD | -1713.872% |
| Aldeyra Therapeutics, Inc. | -42.79 Million USD | -261.129% |
| Cellectis S.A. | -106.62 Million USD | -44.938% |
| Longeveron Inc. | -21.02 Million USD | -634.899% |
| Repare Therapeutics Inc. | -116.22 Million USD | -32.969% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 42.297% |
| Inozyme Pharma, Inc. | -75.64 Million USD | -104.299% |
| Revolution Medicines, Inc. | -487.18 Million USD | 68.279% |
| Nymox Pharmaceutical Corporation | -6.65 Million USD | -2223.241% |
| Third Harmonic Bio, Inc. | -43.95 Million USD | -251.599% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | -107.189% |
| AN2 Therapeutics, Inc. | -69.63 Million USD | -121.931% |
| Anixa Biosciences, Inc. | -11.01 Million USD | -1303.524% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 103.588% |
| Denali Therapeutics Inc. | -196.69 Million USD | 21.432% |
| Revelation Biosciences, Inc. | -8.65 Million USD | -1685.237% |
| Veru Inc. | -93.78 Million USD | -64.788% |
| Corvus Pharmaceuticals, Inc. | -23.32 Million USD | -562.446% |
| Cingulate Inc. | -22.75 Million USD | -579.031% |
| Passage Bio, Inc. | -108.38 Million USD | -42.581% |
| Context Therapeutics Inc. | -25.07 Million USD | -516.378% |
| Exicure, Inc. | -14.99 Million USD | -930.555% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 25.003% |
| Oramed Pharmaceuticals Inc. | -40.59 Million USD | -280.664% |
| Scinai Immunotherapeutics Ltd. | -9.71 Million USD | -1490.439% |
| Rhythm Pharmaceuticals, Inc. | -184.35 Million USD | 16.172% |
| Nuvalent, Inc. | -149.49 Million USD | -3.378% |
| ABVC BioPharma, Inc. | -8.21 Million USD | -1780.872% |
| Carisma Therapeutics, Inc. | -88.73 Million USD | -74.169% |
| Unicycive Therapeutics, Inc. | -20.77 Million USD | -643.92% |
| OmniAb, Inc. | -69.41 Million USD | -122.622% |
| Anew Medical, Inc. | -1.3 Million USD | -11780.17% |
| Fennec Pharmaceuticals Inc. | -12.77 Million USD | -1110.101% |
| Lipocine Inc. | -17.93 Million USD | -761.873% |
| Lexeo Therapeutics, Inc. Common Stock | -68.51 Million USD | -125.566% |
| Nautilus Biotechnology, Inc. | -76.15 Million USD | -102.939% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | -305.885% |
| G1 Therapeutics, Inc. | -39.52 Million USD | -290.978% |
| Bellerophon Therapeutics, Inc. | -22.38 Million USD | -590.413% |
| Sage Therapeutics, Inc. | -579.84 Million USD | 73.348% |
| Ocugen, Inc. | -65.53 Million USD | -135.83% |
| Mind Medicine (MindMed) Inc. | -93.86 Million USD | -64.641% |
| Q32 Bio Inc. | -92.1 Million USD | -67.794% |
| Brainstorm Cell Therapeutics Inc. | -21.43 Million USD | -620.845% |
| Alumis Inc. Common Stock | -158.17 Million USD | 2.296% |
| Equillium, Inc. | -14.52 Million USD | -964.192% |
| Kyverna Therapeutics, Inc. | -62.4 Million USD | -147.64% |
| Coya Therapeutics, Inc. | -7.9 Million USD | -1855.399% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | -719.195% |
| Galera Therapeutics, Inc. | -46.95 Million USD | -229.156% |
| Evelo Biosciences, Inc. | -108.46 Million USD | -42.48% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | -1191.076% |
| Dominari Holdings Inc. | -21.79 Million USD | -609.038% |
| Edesa Biotech, Inc. | -9.22 Million USD | -1575.659% |
| vTv Therapeutics Inc. | -25.5 Million USD | -506.0% |
| Bio-Techne Corporation | 206.68 Million USD | 174.771% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 60.524% |
| Harmony Biosciences Holdings, Inc. | 192.03 Million USD | 180.478% |
| Prelude Therapeutics Incorporated | -132.27 Million USD | -16.832% |
| Candel Therapeutics, Inc. | -38.39 Million USD | -302.547% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | -2.277% |
| Nkarta, Inc. | -131.65 Million USD | -17.389% |
| BioCardia, Inc. | -11.64 Million USD | -1227.224% |
| Iterum Therapeutics plc | -47.46 Million USD | -225.571% |